Genetic determinants of Plasmodium vivax relapse

间日疟原虫复发的遗传决定因素

基本信息

  • 批准号:
    8991706
  • 负责人:
  • 金额:
    $ 16.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-02-01 至 2019-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In recent years, there has been an increased appreciation that global malaria elimination efforts cannot succeed without a better understanding of Plasmodium vivax, the most prevalent malaria species outside Africa. In particular, our poor understanding of P. vivax's ability to establish dormant hypnozoite stages that reactivate to cause periodic relapse is a major barrier to malaria elimination due to the lack of deployable anti-relapse therapy. This proposal will use new genomic technologies to achieve a better understanding of the genetic determinants of vivax relapse, with the ultimate goal of identifying targets for therapeutic intervention. Specifically, in light of limited experimental models of vivax, we will apply next generation sequencing techniques to clinical samples from vivax-infected Cambodian patients to provide the first detailed look at the genetic signatures of relapsing parasites. In Aim 1, we will use amplicon deep sequencing to characterize the in-host diversity of initial and recurrent vivax infections in this cohort. Results will be combined with microsatellite genotyping, population genetic analysis, and statistical modeling to distinguish relapses from re-infections and identify genetic variants predisposed to relapse. We will then whole genome sequence parasites causing relapsing vs. non-relapsing infection in Aim 2 to search for genetic polymorphisms associated with relapse. Our overall hypothesis is that frequently relapsing parasites contain polymorphisms in sporozoite (pre-hypnozoite) specific genes that increase hypnozoite formation and confer increased relapse potential. The candidate is an Assistant Professor in the Division of Infectious Diseases at the University of North Carolina. She has field experience in Southeast Asia, and has pursued clinical and molecular epidemiologic research in malaria for the past 5 years at UNC's Gillings School of Global Public Health. The proposed investigations will build on this foundation to equip her with new skills in genomics, bioinformatics, population genetics, and genetic epidemiology essential for conducting malaria genomics research. She will draw on her mentors' pioneering efforts in next generation sequencing of malaria as well as their respective expertise in malaria epidemiology, population genomics, and the application of these disciplines to public health. The Award will also provide protected time for her to attend didactic courses and hands-on workshops, and to finish a Master's of Science in Clinical Research that includes training in clinical study design. Combined with the preliminary data and tools developed via her research, this training will allow her to pursue R01 funding to conduct genome wide association studies of relapse using large vivax cohorts. The candidate's long-term goal is to become a leading vivax clinical scientist who combines sophisticated molecular tools with clinical studies to help achieve elimination of malaria. Her mentors and her division have a long track record in nurturing successful physician-scientists. They are committed to helping her achieve independence as a translational investigator devoted to understanding the genetic basis of vivax relapse.
描述(由申请人提供):近年来,人们越来越认识到,如果不更好地了解间日疟原虫(非洲以外最流行的疟疾物种),全球消除疟疾的努力就不可能取得成功。特别是,我们对间日疟原虫建立休眠子体阶段并重新激活导致周期性复发的能力了解甚少,这是消除疟疾的一个主要障碍,因为缺乏 可展开的抗复发治疗。该提案将使用新的基因组技术来更好地了解间日疟原虫复发的遗传决定因素,最终目标是确定治疗干预的目标。具体来说,鉴于间日疟原虫的实验模型有限,我们将把下一代测序技术应用于感染间日疟原虫的柬埔寨患者的临床样本,以首次详细了解复发寄生虫的遗传特征。在目标 1 中,我们将使用扩增子深度测序来表征该队列中初始和复发间日疟原虫感染的宿主内多样性。结果将与微卫星基因分型、群体遗传分析和统计模型相结合,以区分复发和再次感染,并识别易于复发的遗传变异。然后,我们将在目标 2 中对引起复发与非复发感染的寄生虫进行全基因组测序,以寻找与复发相关的遗传多态性。我们的总体假设是,经常复发的寄生虫在子孢子(前催眠体)特定基因中含有多态性,这些基因会增加催眠子的形成并增加复发的可能性。该候选人是北卡罗来纳大学传染病系的助理教授。她拥有东南亚的现场经验,过去 5 年一直在北卡罗来纳大学吉林斯全球公共卫生学院从事疟疾的临床和分子流行病学研究。拟议的研究将在此基础上为她提供基因组学、生物信息学、群体遗传学和遗传流行病学方面的新技能,这些技能对于进行疟疾基因组学研究至关重要。她将借鉴导师在下一代疟疾测序方面的开创性努力,以及他们各自在疟疾流行病学、群体基因组学以及这些学科在公共卫生中的应用方面的专业知识。该奖项还将为她提供受保护的时间来参加教学课程和实践研讨会,并完成临床研究理学硕士学位,其中包括临床研究设计培训。结合她的研究开发的初步数据和工具,该培训将使她能够获得 R01 资金,以使用大型间日疟原虫队列进行复发的全基因组关联研究。候选人的长期目标是成为一名领先的间日疟临床科学家,将复杂的分子工具与临床研究相结合,帮助实现消除疟疾。她的导师和她的部门在培养成功的医学科学家方面有着悠久的记录。他们致力于帮助她实现独立,成为一名致力于了解间日疟原虫复发的遗传基础的转化研究者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Lin其他文献

Jessica Lin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessica Lin', 18)}}的其他基金

Does treating low density malaria infections reduce malaria transmission?
治疗低密度疟疾感染是否可以减少疟疾传播?
  • 批准号:
    10574796
  • 财政年份:
    2023
  • 资助金额:
    $ 16.63万
  • 项目类别:
Development of novel diagnostics for African non-falciparum malaria
非洲非恶性疟疾新型诊断方法的开发
  • 批准号:
    10206017
  • 财政年份:
    2020
  • 资助金额:
    $ 16.63万
  • 项目类别:
Development of novel diagnostics for African non-falciparum malaria
非洲非恶性疟疾新型诊断方法的开发
  • 批准号:
    10057106
  • 财政年份:
    2020
  • 资助金额:
    $ 16.63万
  • 项目类别:
Determinants of malaria transmission by submicroscopic gametocytemia
亚显微配子体血症传播疟疾的决定因素
  • 批准号:
    9926215
  • 财政年份:
    2018
  • 资助金额:
    $ 16.63万
  • 项目类别:
Determinants of malaria transmission by submicroscopic gametocytemia
亚显微配子体血症传播疟疾的决定因素
  • 批准号:
    10400098
  • 财政年份:
    2018
  • 资助金额:
    $ 16.63万
  • 项目类别:
Determinants of malaria transmission by submicroscopic gametocytemia
亚显微配子体血症传播疟疾的决定因素
  • 批准号:
    10189493
  • 财政年份:
    2018
  • 资助金额:
    $ 16.63万
  • 项目类别:
Genetic determinants of Plasmodium vivax relapse
间日疟原虫复发的遗传决定因素
  • 批准号:
    8679282
  • 财政年份:
    2014
  • 资助金额:
    $ 16.63万
  • 项目类别:
Genetic determinants of Plasmodium vivax relapse
间日疟原虫复发的遗传决定因素
  • 批准号:
    9222696
  • 财政年份:
    2014
  • 资助金额:
    $ 16.63万
  • 项目类别:

相似国自然基金

非洲猪瘟病毒关键抗原表位筛选和功能验证
  • 批准号:
    32302858
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
非洲猪瘟病毒pS273R通过切割G3BP1调控宿主应激颗粒形成的机制
  • 批准号:
    32302893
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
非洲猪瘟病毒B475L蛋白靶向LMP2抑制抗原递呈的分子机制
  • 批准号:
    32302894
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
自噬在呋虫胺致非洲爪蟾脂质代谢紊乱中的调控机制研究
  • 批准号:
    42307363
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
在非洲精准推广羟基脲的利用和安全
  • 批准号:
    10209231
  • 财政年份:
    2021
  • 资助金额:
    $ 16.63万
  • 项目类别:
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
在非洲精准推广羟基脲的利用和安全
  • 批准号:
    10675756
  • 财政年份:
    2021
  • 资助金额:
    $ 16.63万
  • 项目类别:
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
了解马拉维伯基特淋巴瘤的甲氨蝶呤剂量、药代动力学和毒性
  • 批准号:
    10153913
  • 财政年份:
    2019
  • 资助金额:
    $ 16.63万
  • 项目类别:
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
了解马拉维伯基特淋巴瘤的甲氨蝶呤剂量、药代动力学和毒性
  • 批准号:
    10397542
  • 财政年份:
    2019
  • 资助金额:
    $ 16.63万
  • 项目类别:
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
了解马拉维伯基特淋巴瘤的甲氨蝶呤剂量、药代动力学和毒性
  • 批准号:
    10924460
  • 财政年份:
    2019
  • 资助金额:
    $ 16.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了